Clinicopathologic Significance of Putative Stem Cell Marker, CD44 and CD133, in Human Gastric Carcinoma

Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated. Methods Immunohistochemistry (IHC) was performed to investigate...

Full description

Saved in:

Bibliographic Details
Published in	Journal of surgical oncology Vol. 107; no. 8; pp. 799 - 806
Main Authors	CHEN, SHI, HOU, JING-HUI, FENG, XING-YU, ZHANG, XIAO-SHI, ZHOU, ZHI-WEI, YUN, JING-PING, CHEN, YING-BO, CAI, MU-YAN
Format	Journal Article
Language	English
Published	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2013 Wiley Subscription Services, Inc
Subjects	AC133 Antigen Adult Aged Aged, 80 and over Analysis of Variance Antigens, CD - analysis Biomarkers, Tumor - analysis CD133 CD44 Female gastric carcinoma Gene Expression Regulation, Neoplastic Glycoproteins - analysis Humans Hyaluronan Receptors - analysis Immunohistochemistry Kaplan-Meier Estimate Male Middle Aged Neoplasm Grading Neoplasm Staging Neoplastic Stem Cells Peptides - analysis Phenotype Prognosis ROC Curve Stomach Neoplasms - chemistry Stomach Neoplasms - pathology
Online Access	Get full text
ISSN	0022-4790 1096-9098 1096-9098
DOI	10.1002/jso.23337

Cover

Loading…

Abstract	Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated. Methods Immunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan–Meier plots, and Cox proportional hazards regression model were used to analyze the data. Results The highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high‐expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis. Conclusions Our study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes. J. Surg. Oncol. 2013;107:799–806. © 2013 Wiley Periodicals, Inc.
AbstractList	Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated. Methods Immunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan–Meier plots, and Cox proportional hazards regression model were used to analyze the data. Results The highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high‐expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis. Conclusions Our study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes. J. Surg. Oncol. 2013;107:799–806. © 2013 Wiley Periodicals, Inc. CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated.BACKGROUND AND OBJECTIVESCD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated.Immunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan-Meier plots, and Cox proportional hazards regression model were used to analyze the data.METHODSImmunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan-Meier plots, and Cox proportional hazards regression model were used to analyze the data.The highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high-expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis.RESULTSThe highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high-expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis.Our study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes.CONCLUSIONSOur study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes. Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated. Methods Immunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan-Meier plots, and Cox proportional hazards regression model were used to analyze the data. Results The highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P<0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high-expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis. Conclusions Our study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes. J. Surg. Oncol. 2013;107:799-806. © 2013 Wiley Periodicals, Inc. [PUBLICATION ABSTRACT] CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated. Immunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan-Meier plots, and Cox proportional hazards regression model were used to analyze the data. The highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high-expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis. Our study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes.
Author	CHEN, SHI YUN, JING-PING HOU, JING-HUI CHEN, YING-BO CAI, MU-YAN ZHANG, XIAO-SHI ZHOU, ZHI-WEI FENG, XING-YU
Author_xml	– sequence: 1 givenname: SHI surname: CHEN fullname: CHEN, SHI organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 2 givenname: JING-HUI surname: HOU fullname: HOU, JING-HUI organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 3 givenname: XING-YU surname: FENG fullname: FENG, XING-YU organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 4 givenname: XIAO-SHI surname: ZHANG fullname: ZHANG, XIAO-SHI organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 5 givenname: ZHI-WEI surname: ZHOU fullname: ZHOU, ZHI-WEI organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 6 givenname: JING-PING surname: YUN fullname: YUN, JING-PING organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 7 givenname: YING-BO surname: CHEN fullname: CHEN, YING-BO email: chenyb@sysucc.org.cn organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China – sequence: 8 givenname: MU-YAN surname: CAI fullname: CAI, MU-YAN email: caimuyan@hotmail.com organization: The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/23609373$$D View this record in MEDLINE/PubMed
BookMark	eNp1kU9v1DAQxS1URLeFQ78AstRLkZrWfxI7PlYpbIFCqy7Q3izHcbbeJvZiJ0C_PV52l0MFc_FI_r2nmXl7YMd5ZwA4wOgEI0ROF9GfEEopfwYmGAmWCSTKHTBJfyTLuUC7YC_GBUJICJa_ALuEMiQopxMwrzrrrPZLNdz7zs-thjM7d7a1WjltoG_h9Tiowf4wcDaYHlam6-AnFR5MOIbVeZ5D5ZrUYEqPoXXwYuyVg1MVh5C8KhW0db5XL8HzVnXRvNq8--Dru7dfqovs8mr6vjq7zHROGM8EK5pG4bzluiaKYlO2wvC6xTUtCalxg7lGXKtal2kDxkuMSKsRFkwVqUq6D47Wvsvgv48mDrK3UaeZlTN-jBLTglGOciESevgEXfgxuDTdiiqIwIQXiXq9oca6N41cBtur8Ci3J0zA6RrQwccYTCu1XR3MuyEo20mM5CokmUKSf0JKijdPFFvTf7Eb95-2M4__B-WH2dVWka0VNg7m119FSkwyTnkhbz9P5d23G3H7UZzLgv4GYEushw
CitedBy_id	crossref_primary_10_3390_cancers14061457 crossref_primary_10_1016_j_heliyon_2024_e38662 crossref_primary_10_1186_s12935_021_01840_z crossref_primary_10_1634_theoncologist_2014_0006 crossref_primary_10_2217_fon_2017_0019 crossref_primary_10_1007_s00535_015_1125_5 crossref_primary_10_1186_1471_230X_14_157 crossref_primary_10_1186_s12957_023_03113_7 crossref_primary_10_18621_eurj_1296567 crossref_primary_10_3892_ijo_2015_2966 crossref_primary_10_1007_s10495_013_0949_9 crossref_primary_10_1016_j_canlet_2015_08_005 crossref_primary_10_1007_s13277_015_4155_y crossref_primary_10_12771_emj_2018_41_3_63 crossref_primary_10_3389_fcell_2021_679806 crossref_primary_10_1016_j_biopha_2019_108867 crossref_primary_10_18632_oncotarget_5714 crossref_primary_10_3390_toxins8070199 crossref_primary_10_1016_j_lfs_2021_120050 crossref_primary_10_3389_fmolb_2021_600373 crossref_primary_10_3748_wjg_v21_i4_1329 crossref_primary_10_1177_1758835918794628 crossref_primary_10_18632_oncotarget_4447 crossref_primary_10_7717_peerj_13745 crossref_primary_10_18632_oncotarget_9998 crossref_primary_10_1007_s11888_014_0251_4 crossref_primary_10_1371_journal_pone_0151287 crossref_primary_10_1097_MD_0000000000005163 crossref_primary_10_17116_patol201678247_54 crossref_primary_10_1186_1477_7819_12_368 crossref_primary_10_1371_journal_pone_0153018 crossref_primary_10_1016_j_clinre_2015_11_007 crossref_primary_10_3892_ol_2017_7159 crossref_primary_10_1016_j_pathol_2019_03_009 crossref_primary_10_1155_2024_5553852 crossref_primary_10_1016_j_biopha_2014_08_001 crossref_primary_10_3389_fonc_2019_00428 crossref_primary_10_4103_jcrt_jcrt_1299_22
Cites_doi	10.1111/j.1349-7006.2004.tb03179.x 10.1089/scd.2010.0455 10.1016/j.ejca.2005.07.034 10.1038/nrc2499 10.1016/0092-8674(91)90403-L 10.1016/j.ccr.2011.01.038 10.1016/j.canlet.2011.10.012 10.1158/1055-9965.EPI-10-0437 10.1016/j.bbrc.2006.11.029 10.1111/j.1349-7006.2010.01560.x 10.1002/stem.1061 10.1158/0008-5472.CAN-05-2018 10.3109/15419069509081288 10.1073/pnas.0609490104 10.1634/stemcells.2007-0409 10.1016/j.cell.2008.03.027 10.1038/sj.cdd.4402283 10.1016/j.ejca.2007.01.017 10.1038/labinvest.3700112 10.1038/sj.bjc.6605001 10.1002/stem.236 10.1097/00042737-200309000-00007 10.1038/sj.bjc.6604437 10.1038/sj.onc.1210811 10.1186/bcr1610 10.1186/1756-9966-29-141 10.1038/nature05372 10.1111/j.1349-7006.2011.01947.x 10.1038/nature05384 10.1054/bjoc.2001.1922 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C 10.1681/ASN.2006010089 10.1182/blood.V90.12.5002 10.1002/stem.30 10.1038/nature03128 10.1073/pnas.0530291100 10.1038/nrm1004 10.1016/S0065-230X(08)60101-3 10.1038/sj.jid.5700665 10.1182/blood.V90.12.5013 10.1053/j.gastro.2007.04.025 10.1016/j.stem.2007.06.002 10.1038/sj.bjc.6605762 10.2174/1568009053765771 10.1186/1471-2407-10-218
ContentType	Journal Article
Copyright	Copyright © 2013 Wiley Periodicals, Inc.
Copyright_xml	– notice: Copyright © 2013 Wiley Periodicals, Inc.
DBID	BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8
DOI	10.1002/jso.23337
DatabaseName	Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1096-9098
EndPage	806
ExternalDocumentID	2979410711 23609373 10_1002_jso_23337 JSO23337 ark_67375_WNG_XVR9WK9D_5
Genre	article Journal Article
GroupedDBID	--- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 V2E V8K W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGQPQ AGYGG CITATION .55 .GJ 31~ 3O- 53G AAQQT ABEML ACSCC AFFNX AGHNM CGR CUY CVF ECM EIF FEDTE GLUZI HF~ HVGLF M6P NPM PALCI RIWAO RJQFR SAMSI X7M ZGI ZXP AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8
ID	FETCH-LOGICAL-c4267-965dda14f7cb2a31e8f9e7bf1b3822b1d17c07cabc8609678102fc0196a555583
IEDL.DBID	DR2
ISSN	0022-4790 1096-9098
IngestDate	Fri Jul 11 05:27:29 EDT 2025 Sun Jul 13 05:02:54 EDT 2025 Thu Apr 03 06:56:54 EDT 2025 Thu Apr 24 23:07:58 EDT 2025 Tue Jul 01 03:18:43 EDT 2025 Wed Jan 22 16:31:56 EST 2025 Wed Oct 30 09:51:53 EDT 2024
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	8
Language	English
License	http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2013 Wiley Periodicals, Inc.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4267-965dda14f7cb2a31e8f9e7bf1b3822b1d17c07cabc8609678102fc0196a555583
Notes	Ying-Bo Chen and Mu-Yan Cai contributed equally to this work. Conflict of interest statement: None declared. istex:3DD1586DB1A9DB4754669342F7816DC30EF8CA0C ark:/67375/WNG-XVR9WK9D-5 ArticleID:JSO23337 Ying‐Bo Chen and Mu‐Yan Cai contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.23337
PMID	23609373
PQID	1355291275
PQPubID	1016364
PageCount	8
ParticipantIDs	proquest_miscellaneous_1356370499 proquest_journals_1355291275 pubmed_primary_23609373 crossref_citationtrail_10_1002_jso_23337 crossref_primary_10_1002_jso_23337 wiley_primary_10_1002_jso_23337_JSO23337 istex_primary_ark_67375_WNG_XVR9WK9D_5
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2013-06-01
PublicationDateYYYYMMDD	2013-06-01
PublicationDate_xml	– month: 06 year: 2013 text: 2013-06-01 day: 01
PublicationDecade	2010
PublicationPlace	Hoboken
PublicationPlace_xml	– name: Hoboken – name: United States
PublicationTitle	Journal of surgical oncology
PublicationTitleAlternate	J. Surg. Oncol
PublicationYear	2013
Publisher	Wiley Subscription Services, Inc., A Wiley Company Wiley Subscription Services, Inc
Publisher_xml	– name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley Subscription Services, Inc
References	Smith LM, Nesterova A, Ryan MC, et al.: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-109. Ma S, Chan KW, Hu L, et al.: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556. Heider KH, Dammrich J, Skroch-Angel P, et al.: Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-4203. Eramo A, Lotti F, Sette G, et al.: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514. Sagrinati C, Netti GS, Mazzinghi B, et al.: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006;17:2443-2456. Ito Y, Hamazaki TS, Ohnuma K, et al.: Isolation of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol 2007;127:1052-1060. Sugiyama T, Rodriguez RT, McLean GW, et al.: Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc Natl Acad Sci USA 2007;104:175-180. Hermann PC, Huber SL, Herrler T, et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323. Yin AH, Miraglia S, Zanjani ED, et al.: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012. Piao LS, Hur W, Kim TK, et al.: CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012;315:129-137. Yu JW, Zhang P, Wu JG, et al.: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res 2010;29:141. Avital I, Moreira AL, Klimstra DS, et al.: Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007;25:2903-2909. Yasui W, Kudo Y, Naka K, et al.: Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: Relation to the proliferation and progression. Int J Oncol 1998;12:1253-1258. Okayama H, Kumamoto K, Saitou K, et al.: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 2009;22:745-755. Monzani E, Facchetti F, Galmozzi E, et al.: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935-946. Mani SA, Guo W, Liao MJ, et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715. O'Brien CA, Pollett A, Gallinger S, et al.: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. Gunthert U, Hofmann M, Rudy W, et al.: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24. Kordes C, Sawitza I, Muller-Marbach A, et al.: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 2007;352:410-417. Hari D, Xin HW, Jaiswal K, et al.: Isolation of live label-retaining cells and cells undergoing asymmetric cell division via nonrandom chromosomal cosegregation from human cancers. Stem Cells Dev 2011;20:1649-1658. Ponta H, Sherman L, Herrlich PA: C D44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. Xin HW, Hari DM, Mullinax JE, et al.: Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012;30:591-598. Bianco R, Melisi D, Ciardiello F, et al.: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006;42:290-294. Muller W, Schneiders A, Heider KH, et al.: Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997;183:222-227. Takaishi S, Okumura T, Tu S, et al.: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-1020. Omara-Opyene AL, Qiu J, Shah GV, et al.: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004;84:894-907. Nagano O, Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004;95:930-935. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115. Miraglia S, Godfrey W, Yin AH, et al.: A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021. Sheridan C, Kishimoto H, Fuchs RK, et al.: CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006;8:R59. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768. Gulmann C, Grace A, Leader M, et al.: CD44v6: A potential marker of malignant transformation in intestinal metaplasia of the stomach? An immunohistochemical study using tissue microarrays. Eur J Gastroenterol Hepatol 2003;15:981-986. Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005;5:171-193. Boegl M, Prinz C: CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 2009;100:1365-1366; author reply 1367. Wheatley SC, Isacke CM: Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation. Cell Adhes Commun 1995;3:217-230. Fukamachi H, Shimada S, Ito K, et al.: CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci 2011;102:1313-1321. Li Y, Heldin P: Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer 2001;85:600-607. Ma S, Lee TK, Zheng BJ, et al.: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-1758. Naor D, Sionov RV, Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319. Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004; 327-349. Collins AT, Berry PA, Hyde C, et al.: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951. Curley MD, Therrien VA, Cummings CL, et al.: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009;27:2875-2883. Ishimoto T, Nagano O, Yae T, et al.: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400. Singh SK, Hawkins C, Clarke ID, et al.: Identification of human brain tumour initiating cells. Nature 2004;432:396-401. Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010;10:218. Lugli A, Iezzi G, Hostettler I, et al.: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-390. Cai MY, Zhang B, He WP, et al.: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 101:1543-1549. Jemal A, Center MM, DeSantis C, et al.: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907. 2007; 104 2007; 445 2009; 22 2010; 10 2004; 84 2007; 127 2010; 19 2010; 103 2006; 17 2006; 8 2008; 15 2003; 15 2005; 65 2008; 8 2008; 99 2004 2011; 19 1995; 3 2009; 27 2001; 85 2012; 30 1997; 90 2011; 102 2006; 42 2004; 95 1997; 71 2004; 432 1997; 183 1991; 65 2010; 29 2007; 352 2007; 132 1993; 53 2008; 27 2005; 5 2011; 20 2009; 100 2003; 4 101 2008; 133 2007; 43 2007; 1 2012; 315 2003; 100 1998; 12 2007; 25 e_1_2_5_27_2 e_1_2_5_48_2 e_1_2_5_25_2 e_1_2_5_46_2 e_1_2_5_23_2 e_1_2_5_44_2 e_1_2_5_21_2 Heider KH (e_1_2_5_37_2) 1993; 53 e_1_2_5_29_2 Tahara E (e_1_2_5_38_2) 2004 e_1_2_5_40_2 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_7_2 e_1_2_5_34_2 e_1_2_5_5_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_3_2 e_1_2_5_17_2 e_1_2_5_19_2 Cai MY (e_1_2_5_30_2); 101 e_1_2_5_26_2 e_1_2_5_49_2 e_1_2_5_24_2 e_1_2_5_47_2 e_1_2_5_22_2 e_1_2_5_45_2 e_1_2_5_20_2 e_1_2_5_43_2 e_1_2_5_28_2 e_1_2_5_41_2 Okayama H (e_1_2_5_42_2) 2009; 22 e_1_2_5_14_2 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_8_2 e_1_2_5_10_2 e_1_2_5_33_2 e_1_2_5_6_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_2_2 e_1_2_5_18_2 Yasui W (e_1_2_5_50_2) 1998; 12 e_1_2_5_39_2
References_xml	– reference: Heider KH, Dammrich J, Skroch-Angel P, et al.: Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-4203. – reference: Eramo A, Lotti F, Sette G, et al.: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514. – reference: Jemal A, Center MM, DeSantis C, et al.: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907. – reference: Piao LS, Hur W, Kim TK, et al.: CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012;315:129-137. – reference: Naor D, Sionov RV, Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319. – reference: Yasui W, Kudo Y, Naka K, et al.: Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: Relation to the proliferation and progression. Int J Oncol 1998;12:1253-1258. – reference: Boegl M, Prinz C: CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 2009;100:1365-1366; author reply 1367. – reference: Miraglia S, Godfrey W, Yin AH, et al.: A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021. – reference: Xin HW, Hari DM, Mullinax JE, et al.: Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012;30:591-598. – reference: Omara-Opyene AL, Qiu J, Shah GV, et al.: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004;84:894-907. – reference: Curley MD, Therrien VA, Cummings CL, et al.: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009;27:2875-2883. – reference: Yin AH, Miraglia S, Zanjani ED, et al.: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012. – reference: Sugiyama T, Rodriguez RT, McLean GW, et al.: Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc Natl Acad Sci USA 2007;104:175-180. – reference: Ito Y, Hamazaki TS, Ohnuma K, et al.: Isolation of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol 2007;127:1052-1060. – reference: Avital I, Moreira AL, Klimstra DS, et al.: Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007;25:2903-2909. – reference: Gulmann C, Grace A, Leader M, et al.: CD44v6: A potential marker of malignant transformation in intestinal metaplasia of the stomach? An immunohistochemical study using tissue microarrays. Eur J Gastroenterol Hepatol 2003;15:981-986. – reference: Bianco R, Melisi D, Ciardiello F, et al.: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006;42:290-294. – reference: Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005;5:171-193. – reference: Lugli A, Iezzi G, Hostettler I, et al.: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-390. – reference: Muller W, Schneiders A, Heider KH, et al.: Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997;183:222-227. – reference: Okayama H, Kumamoto K, Saitou K, et al.: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 2009;22:745-755. – reference: Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. – reference: Monzani E, Facchetti F, Galmozzi E, et al.: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935-946. – reference: Hermann PC, Huber SL, Herrler T, et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323. – reference: Takaishi S, Okumura T, Tu S, et al.: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-1020. – reference: Sheridan C, Kishimoto H, Fuchs RK, et al.: CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006;8:R59. – reference: O'Brien CA, Pollett A, Gallinger S, et al.: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. – reference: Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010;10:218. – reference: Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004; 327-349. – reference: Kordes C, Sawitza I, Muller-Marbach A, et al.: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 2007;352:410-417. – reference: Ponta H, Sherman L, Herrlich PA: C D44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. – reference: Ma S, Lee TK, Zheng BJ, et al.: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-1758. – reference: Cai MY, Zhang B, He WP, et al.: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 101:1543-1549. – reference: Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768. – reference: Ishimoto T, Nagano O, Yae T, et al.: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400. – reference: Collins AT, Berry PA, Hyde C, et al.: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951. – reference: Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115. – reference: Sagrinati C, Netti GS, Mazzinghi B, et al.: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006;17:2443-2456. – reference: Yu JW, Zhang P, Wu JG, et al.: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res 2010;29:141. – reference: Fukamachi H, Shimada S, Ito K, et al.: CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci 2011;102:1313-1321. – reference: Wheatley SC, Isacke CM: Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation. Cell Adhes Commun 1995;3:217-230. – reference: Hari D, Xin HW, Jaiswal K, et al.: Isolation of live label-retaining cells and cells undergoing asymmetric cell division via nonrandom chromosomal cosegregation from human cancers. Stem Cells Dev 2011;20:1649-1658. – reference: Gunthert U, Hofmann M, Rudy W, et al.: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24. – reference: Ma S, Chan KW, Hu L, et al.: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556. – reference: Nagano O, Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004;95:930-935. – reference: Li Y, Heldin P: Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer 2001;85:600-607. – reference: Singh SK, Hawkins C, Clarke ID, et al.: Identification of human brain tumour initiating cells. Nature 2004;432:396-401. – reference: Mani SA, Guo W, Liao MJ, et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715. – reference: Smith LM, Nesterova A, Ryan MC, et al.: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-109. – volume: 27 start-page: 1749 year: 2008 end-page: 1758 article-title: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway publication-title: Oncogene – volume: 101 start-page: 1543 end-page: 1549 article-title: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma publication-title: Cancer Sci – volume: 12 start-page: 1253 year: 1998 end-page: 1258 article-title: Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: Relation to the proliferation and progression publication-title: Int J Oncol – volume: 8 start-page: 755 year: 2008 end-page: 768 article-title: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions publication-title: Nat Rev Cancer – volume: 65 start-page: 13 year: 1991 end-page: 24 article-title: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells publication-title: Cell – volume: 104 start-page: 175 year: 2007 end-page: 180 article-title: Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS publication-title: Proc Natl Acad Sci USA – volume: 127 start-page: 1052 year: 2007 end-page: 1060 article-title: Isolation of murine hair‐inducing cells using the cell surface marker prominin‐1/CD133 publication-title: J Invest Dermatol – volume: 29 start-page: 141 year: 2010 article-title: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma publication-title: J Exp Clin Cancer Res – volume: 8 start-page: R59 year: 2006 article-title: CD44+/CD24‐breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis publication-title: Breast Cancer Res – volume: 27 start-page: 1006 year: 2009 end-page: 1020 article-title: Identification of gastric cancer stem cells using the cell surface marker CD44 publication-title: Stem Cells – volume: 15 start-page: 504 year: 2008 end-page: 514 article-title: Identification and expansion of the tumorigenic lung cancer stem cell population publication-title: Cell Death Differ – volume: 20 start-page: 1649 year: 2011 end-page: 1658 article-title: Isolation of live label‐retaining cells and cells undergoing asymmetric cell division via nonrandom chromosomal cosegregation from human cancers publication-title: Stem Cells Dev – volume: 103 start-page: 382 year: 2010 end-page: 390 article-title: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer publication-title: Br J Cancer – volume: 315 start-page: 129 year: 2012 end-page: 137 article-title: CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma publication-title: Cancer Lett – volume: 3 start-page: 217 year: 1995 end-page: 230 article-title: Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation publication-title: Cell Adhes Commun – volume: 90 start-page: 5002 year: 1997 end-page: 5012 article-title: AC133, a novel marker for human hematopoietic stem and progenitor cells publication-title: Blood – volume: 53 start-page: 4197 year: 1993 end-page: 4203 article-title: Differential expression of CD44 splice variants in intestinal‐ and diffuse‐type human gastric carcinomas and normal gastric mucosa publication-title: Cancer Res – volume: 4 start-page: 33 year: 2003 end-page: 45 article-title: C D44: From adhesion molecules to signalling regulators publication-title: Nat Rev Mol Cell Biol – volume: 25 start-page: 2903 year: 2007 end-page: 2909 article-title: Donor‐derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation publication-title: Stem Cells – volume: 19 start-page: 387 year: 2011 end-page: 400 article-title: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth publication-title: Cancer Cell – volume: 432 start-page: 396 year: 2004 end-page: 401 article-title: Identification of human brain tumour initiating cells publication-title: Nature – volume: 71 start-page: 241 year: 1997 end-page: 319 article-title: CD44: Structure, function, and association with the malignant process publication-title: Adv Cancer Res – start-page: 327 year: 2004 end-page: 349 article-title: Genetic pathways of two types of gastric cancer publication-title: IARC Sci Publ – volume: 19 start-page: 1893 year: 2010 end-page: 1907 article-title: Global patterns of cancer incidence and mortality rates and trends publication-title: Cancer Epidemiol Biomarkers Prev – volume: 133 start-page: 704 year: 2008 end-page: 715 article-title: The epithelial‐mesenchymal transition generates cells with properties of stem cells publication-title: Cell – volume: 17 start-page: 2443 year: 2006 end-page: 2456 article-title: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys publication-title: J Am Soc Nephrol – volume: 85 start-page: 600 year: 2001 end-page: 607 article-title: Hyaluronan production increases the malignant properties of mesothelioma cells publication-title: Br J Cancer – volume: 43 start-page: 935 year: 2007 end-page: 946 article-title: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential publication-title: Eur J Cancer – volume: 445 start-page: 106 year: 2007 end-page: 110 article-title: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice publication-title: Nature – volume: 102 start-page: 1313 year: 2011 end-page: 1321 article-title: CD133 is a marker of gland‐forming cells in gastric tumors and Sox17 is involved in its regulation publication-title: Cancer Sci – volume: 15 start-page: 981 year: 2003 end-page: 986 article-title: CD44v6: A potential marker of malignant transformation in intestinal metaplasia of the stomach? An immunohistochemical study using tissue microarrays publication-title: Eur J Gastroenterol Hepatol – volume: 27 start-page: 2875 year: 2009 end-page: 2883 article-title: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer publication-title: Stem Cells – volume: 99 start-page: 100 year: 2008 end-page: 109 article-title: CD133/prominin‐1 is a potential therapeutic target for antibody‐drug conjugates in hepatocellular and gastric cancers publication-title: Br J Cancer – volume: 183 start-page: 222 year: 1997 end-page: 227 article-title: Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer publication-title: J Pathol – volume: 100 start-page: 1365 year: 2009 end-page: 1366; article-title: CD133 expression in different stages of gastric adenocarcinoma publication-title: Br J Cancer – volume: 95 start-page: 930 year: 2004 end-page: 935 article-title: Mechanism and biological significance of CD44 cleavage publication-title: Cancer Sci – volume: 132 start-page: 2542 year: 2007 end-page: 2556 article-title: Identification and characterization of tumorigenic liver cancer stem/progenitor cells publication-title: Gastroenterology – volume: 42 start-page: 290 year: 2006 end-page: 294 article-title: Key cancer cell signal transduction pathways as therapeutic targets publication-title: Eur J Cancer – volume: 30 start-page: 591 year: 2012 end-page: 598 article-title: Tumor‐initiating label‐retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division publication-title: Stem Cells – volume: 90 start-page: 5013 year: 1997 end-page: 5021 article-title: A novel five‐transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning publication-title: Blood – volume: 65 start-page: 10946 year: 2005 end-page: 10951 article-title: Prospective identification of tumorigenic prostate cancer stem cells publication-title: Cancer Res – volume: 5 start-page: 171 year: 2005 end-page: 193 article-title: Molecularly targeted therapy for gastrointestinal cancer publication-title: Curr Cancer Drug Targets – volume: 22 start-page: 745 year: 2009 end-page: 755 article-title: CD44v6, MMP‐7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer publication-title: Oncol Rep – volume: 10 start-page: 218 year: 2010 article-title: Aberrant expression of CD133 protein correlates with Ki‐67 expression and is a prognostic marker in gastric adenocarcinoma publication-title: BMC Cancer – volume: 1 start-page: 313 year: 2007 end-page: 323 article-title: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer publication-title: Cell Stem Cell – volume: 352 start-page: 410 year: 2007 end-page: 417 article-title: CD133+ hepatic stellate cells are progenitor cells publication-title: Biochem Biophys Res Commun – volume: 445 start-page: 111 year: 2007 end-page: 115 article-title: Identification and expansion of human colon‐cancer‐initiating cells publication-title: Nature – volume: 100 start-page: 3983 year: 2003 end-page: 3988 article-title: Prospective identification of tumorigenic breast cancer cells publication-title: Proc Natl Acad Sci USA – volume: 84 start-page: 894 year: 2004 end-page: 907 article-title: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18 publication-title: Lab Invest – ident: e_1_2_5_5_2 doi: 10.1111/j.1349-7006.2004.tb03179.x – ident: e_1_2_5_34_2 doi: 10.1089/scd.2010.0455 – ident: e_1_2_5_3_2 doi: 10.1016/j.ejca.2005.07.034 – ident: e_1_2_5_31_2 doi: 10.1038/nrc2499 – ident: e_1_2_5_41_2 doi: 10.1016/0092-8674(91)90403-L – ident: e_1_2_5_43_2 doi: 10.1016/j.ccr.2011.01.038 – ident: e_1_2_5_48_2 doi: 10.1016/j.canlet.2011.10.012 – start-page: 327 year: 2004 ident: e_1_2_5_38_2 article-title: Genetic pathways of two types of gastric cancer publication-title: IARC Sci Publ – volume: 22 start-page: 745 year: 2009 ident: e_1_2_5_42_2 article-title: CD44v6, MMP‐7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer publication-title: Oncol Rep – ident: e_1_2_5_2_2 doi: 10.1158/1055-9965.EPI-10-0437 – ident: e_1_2_5_18_2 doi: 10.1016/j.bbrc.2006.11.029 – volume: 101 start-page: 1543 ident: e_1_2_5_30_2 article-title: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01560.x – ident: e_1_2_5_32_2 doi: 10.1002/stem.1061 – volume: 12 start-page: 1253 year: 1998 ident: e_1_2_5_50_2 article-title: Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: Relation to the proliferation and progression publication-title: Int J Oncol – ident: e_1_2_5_23_2 doi: 10.1158/0008-5472.CAN-05-2018 – ident: e_1_2_5_9_2 doi: 10.3109/15419069509081288 – ident: e_1_2_5_17_2 doi: 10.1073/pnas.0609490104 – ident: e_1_2_5_33_2 doi: 10.1634/stemcells.2007-0409 – ident: e_1_2_5_10_2 doi: 10.1016/j.cell.2008.03.027 – ident: e_1_2_5_24_2 doi: 10.1038/sj.cdd.4402283 – ident: e_1_2_5_25_2 doi: 10.1016/j.ejca.2007.01.017 – ident: e_1_2_5_12_2 doi: 10.1038/labinvest.3700112 – ident: e_1_2_5_29_2 doi: 10.1038/sj.bjc.6605001 – ident: e_1_2_5_26_2 doi: 10.1002/stem.236 – ident: e_1_2_5_36_2 doi: 10.1097/00042737-200309000-00007 – ident: e_1_2_5_28_2 doi: 10.1038/sj.bjc.6604437 – ident: e_1_2_5_47_2 doi: 10.1038/sj.onc.1210811 – ident: e_1_2_5_11_2 doi: 10.1186/bcr1610 – ident: e_1_2_5_49_2 doi: 10.1186/1756-9966-29-141 – ident: e_1_2_5_44_2 doi: 10.1038/nature05372 – ident: e_1_2_5_45_2 doi: 10.1111/j.1349-7006.2011.01947.x – ident: e_1_2_5_22_2 doi: 10.1038/nature05384 – ident: e_1_2_5_13_2 doi: 10.1054/bjoc.2001.1922 – ident: e_1_2_5_39_2 doi: 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C – ident: e_1_2_5_16_2 doi: 10.1681/ASN.2006010089 – ident: e_1_2_5_14_2 doi: 10.1182/blood.V90.12.5002 – ident: e_1_2_5_40_2 doi: 10.1002/stem.30 – ident: e_1_2_5_20_2 doi: 10.1038/nature03128 – volume: 53 start-page: 4197 year: 1993 ident: e_1_2_5_37_2 article-title: Differential expression of CD44 splice variants in intestinal‐ and diffuse‐type human gastric carcinomas and normal gastric mucosa publication-title: Cancer Res – ident: e_1_2_5_8_2 doi: 10.1073/pnas.0530291100 – ident: e_1_2_5_6_2 doi: 10.1038/nrm1004 – ident: e_1_2_5_7_2 doi: 10.1016/S0065-230X(08)60101-3 – ident: e_1_2_5_19_2 doi: 10.1038/sj.jid.5700665 – ident: e_1_2_5_15_2 doi: 10.1182/blood.V90.12.5013 – ident: e_1_2_5_21_2 doi: 10.1053/j.gastro.2007.04.025 – ident: e_1_2_5_27_2 doi: 10.1016/j.stem.2007.06.002 – ident: e_1_2_5_35_2 doi: 10.1038/sj.bjc.6605762 – ident: e_1_2_5_4_2 doi: 10.2174/1568009053765771 – ident: e_1_2_5_46_2 doi: 10.1186/1471-2407-10-218
SSID	ssj0009964
Score	2.252636
Snippet	Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133... CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with... Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133...
SourceID	proquest pubmed crossref wiley istex
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	799
SubjectTerms	AC133 Antigen Adult Aged Aged, 80 and over Analysis of Variance Antigens, CD - analysis Biomarkers, Tumor - analysis CD133 CD44 Female gastric carcinoma Gene Expression Regulation, Neoplastic Glycoproteins - analysis Humans Hyaluronan Receptors - analysis Immunohistochemistry Kaplan-Meier Estimate Male Middle Aged Neoplasm Grading Neoplasm Staging Neoplastic Stem Cells Peptides - analysis Phenotype Prognosis ROC Curve Stomach Neoplasms - chemistry Stomach Neoplasms - pathology
Title	Clinicopathologic Significance of Putative Stem Cell Marker, CD44 and CD133, in Human Gastric Carcinoma
URI	https://api.istex.fr/ark:/67375/WNG-XVR9WK9D-5/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjso.23337 https://www.ncbi.nlm.nih.gov/pubmed/23609373 https://www.proquest.com/docview/1355291275 https://www.proquest.com/docview/1356370499
Volume	107
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF9KBfHF74-0VVYR8aG5JrtJNotPcrUtlVbpWXsPhWW_UqrXRHo5EP96ZzaXlEoF8W0hE7I7O7Pzm-zubwh5LV1S2EJAWuKMgwRFVrEWuY2r3GkJ4dgVHi84HxwWe8fZ_jSfrpB3_V2Yjh9i-OGGnhHWa3RwbeZbV6Sh3-bNiHHO8SY5ntVCQHR0RR0FOD7rmcIzIZOeVShhW8Ob12LRLVTrz5uA5nXcGgLPzj1y2ne5O2_yfbRozcj--oPN8T_HdJ_cXQJS-r6zoAdkxdcPye2D5Zb7I3LWMYc2WLq4Wyjp5PysxhNGaDC0qejnRRvow-mk9Rd07GczileA_OUmHW9nGdW1gwakqZv0vKZh24DuaiwYYukYaxnVzYV-TI53PnwZ78XL6gyxhaguYlnkzuk0q4Q1TPPUl5X0wlSp4QA6TOpSYRNhtbFlAXmSKAHKVBbpeHSOJGP8CVmtm9o_I1R4CYFUcyY9yxxkrJrjGmyKMhGVLllE3vbzpOySuhwraMxUR7rMFChOBcVF5NUg-qPj67hJ6E2Y7EECdIIH3ESuTg531fTrkTz5KLdVHpGN3hrU0rfnKgWIxiQS40fk5fAYvBK3WnTtm0WQKbjAdDIiTzsrGj7GOOiDCw6jCrbw936q_cmn0Fj7d9F1cod1FTviJN0gq-3lwj8H3NSaF8FBfgNH4w9w
linkProvider	Wiley-Blackwell
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVoJeeEMDBQxCiEOzTewkjiUuaEu7tN0FdVu6F2Q5jlMVtglqsxLi1-NxHlVRkRA3S5koznjG840f3wC8FnmQ6ITbtCTPcpugiMJXPNZ-EedK2HCcJwYvOI8nyego2p3FsyV4192Fafgh-gU39Aw3X6OD44L05iVr6LeLakAZY_wGrGBFb5dQHVySR1kkH3Vc4REXQccrFNDN_tUr0WgFFfvzOqh5Fbm60LN9B752nW5OnHwfLOpsoH_9wef4v391F263mJS8b4zoHiyZ8j7cHLe77g_gpCEPrbB6cTNXkunpSYmHjNBmSFWQz4vaMYiTaW3OyNDM5wRvAZnzDTLciiKiytw2bKa6QU5L4nYOyI7CmiGaDLGcUVmdqYdwtP3hcDjy2wINvraBnfsiifNchVHBdUYVC01aCMOzIsyYxR1ZmIdcB1yrTKeJTZV4atFMoZGRR8XIM8YewXJZlWYNCDfCxlLFqDA0ym3SqhhOw1mSBrxQKfXgbTdQUrfs5VhEYy4b3mUqreKkU5wHr3rRHw1lx3VCb9xo9xJWJ3jGjcfyeLIjZ18OxPGe2JKxB-udOcjWvS9kaFEaFciN78HL_rF1TNxtUaWpFk4mYRwzSg8eN2bUf4wyqw_Gmf0rZwx_76fcnX5yjSf_LvoCbo0Ox_ty_-Nk7yms0qaAhx-E67Bcny_MMwuj6uy585bfO3UTiw
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVqq4lDcEChiEEIdmm9hJHIsT2mVbWrpUXUr3gGQ5flQt26RqsxLi12M7j6qoSIibpUwUezzj-Sa2vwF4w1SUyYzatEQVyiYozISCpjI0qRLMhmOVaXfBeW-SbR8mO7N0tgTvu7swDT9E_8PNeYZfr52DnyuzeUUaenpZDTAhhN6ClSSLcmfSo4Mr7igL5JOOKjyhLOpohSK82b96LRitOL3-vAlpXgeuPvKM78D3rs_NgZMfg0VdDOSvP-gc_3NQd2GtRaToQ2NC92BJl_dhda_dc38Axw11aOVqFzcrJZqeHJfuiJGzGFQZtL-oPX84mtb6DA31fI7cHSB9sYGGoyRBolS2YfPUDXRSIr9vgLaEqxgi0dAVMyqrM_EQDscfvw63w7Y8QyhtWKchy1KlRJwYKgssSKxzwzQtTFwQizqKWMVURlSKQuaZTZRobrGMkY6PR6SOZYw8guWyKvUTQFQzG0kFwUzjRNmUVRC3CBdZHlEjchzAu26euGy5y10JjTlvWJcxt4rjXnEBvO5FzxvCjpuE3vrJ7iWsTtwJN5ryo8kWn307YEe7bMTTANY7a-Ctc1_y2GI0zBwzfgCv-sfWLd1eiyh1tfAyGaEunwzgcWNF_ccwsfoglNhReVv4ez_5zvSLbzz9d9GXsLo_GvPPnya7z-A2bqp3hFG8Dsv1xUI_txiqLl54X_kNB0sSQw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinicopathologic+significance+of+putative+stem+cell+marker%2C+CD44+and+CD133%2C+in+human+gastric+carcinoma&rft.jtitle=Journal+of+surgical+oncology&rft.au=Chen%2C+Shi&rft.au=Hou%2C+Jing-Hui&rft.au=Feng%2C+Xing-Yu&rft.au=Zhang%2C+Xiao-Shi&rft.date=2013-06-01&rft.eissn=1096-9098&rft.volume=107&rft.issue=8&rft.spage=799&rft_id=info:doi/10.1002%2Fjso.23337&rft_id=info%3Apmid%2F23609373&rft.externalDocID=23609373
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-4790&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-4790&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-4790&client=summon